Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Operating Expenses (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Operating Expenses data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, Operating Expenses fell 91.52% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $88.5 million, down 29.34%, while the annual FY2025 figure was $93.4 million, 25.45% down from the prior year.
  • Operating Expenses reached $2.3 million in Q4 2025 per FHTX's latest filing, down from $26.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $38.6 million in Q1 2023 and bottomed at $2.3 million in Q4 2025.
  • Average Operating Expenses over 5 years is $29.7 million, with a median of $31.4 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 70.62% in 2021, then crashed 91.52% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $28.8 million in 2021, then grew by 25.26% to $36.1 million in 2022, then decreased by 13.43% to $31.2 million in 2023, then dropped by 13.98% to $26.9 million in 2024, then plummeted by 91.52% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $2.3 million in Q4 2025, $26.7 million in Q3 2025, and $28.7 million in Q2 2025.